Innoviva Inc. Stock
Innoviva Inc. Stock
Innoviva Inc. shows a slight decrease today, losing -€0.100 (-0.610%) compared to yesterday.
Innoviva Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
As a result the target price of 26 € shows a very positive potential of 59.51% compared to the current price of 16.3 € for Innoviva Inc..
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | -0.610% | -1.807% | -1.807% | -9.945% | -0.610% | 41.739% | 65.482% |
| Rockwell Medical Inc. | -1.040% | -14.198% | 28.065% | -53.089% | 33.555% | -42.452% | -92.251% |
| Pacira Pharmaceuticals | -0.580% | 4.242% | -20.370% | -27.731% | -20.370% | -51.136% | -69.286% |
| Twist Bioscience Corp | -0.810% | -0.366% | 23.329% | -28.904% | 27.181% | 37.955% | -73.368% |
Comments
Innoviva (NASDAQ:INVA) had its price target raised by analysts at HC Wainwright from $45.00 to $46.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) had its price target raised by analysts at Cantor Fitzgerald from $29.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
News
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also
Innoviva (INVA) Q2 Sales Jump 64%
Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share
